My 48yr old daughter underwent an operation in 2020 for ovarian cancer. The cancer was Stage 3c ovarian cancer. She is a BRCA1 carrier. After 6 rounds of chemotherapy, she was put on Olaparib around April 2021. Her hospital Hospital has now ceased prescribing her the drug on the basis of guidance from NICE.
Can anyone, either member of the forum or CRUK specialist clarify as to whether this decision has been taken purely on cost grounds or whether there is any benefit to be gained through continued administration of Olaparib beyond 2 years?